Antifungal Activity of Geldanamycin Alone or in Combination with Fluconazole Against Candida species

Mycopathologia

Volumn 175, Issue 3-4, 2013, Pages 273-279

  Zhang, Jinqing ^a   Liu, Wei ^a   Tan, Jingwen ^a   Sun, Yi ^a   Wan, Zhe ^a   Li, Ruoyu ^a  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

Author keywords

Antifungal activity; Candida species; Fluconazole; Geldanamycin

Indexed keywords

CANDIDA; CANDIDA ALBICANS;

EID: 84876089804     PISSN: 0301486X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11046-012-9612-1     Document Type: Article

References (28)

1. Wilson DT, Drew RH, Perfect JR. Antifungal therapy for invasive fungal diseases in allogeneic stem cell transplant recipients: an update. Mycopathologia. 2009; 168: 313-27.
2. Koziol-Montewka M, Magrys A, Paluch-Oles J, Bogut A, Buczynski K, Jablonka S. MPO and cytokines in the serum of cancer patients in the context of Candida colonization and infection. Immunol Invest. 2006; 35: 167-79.
3. Rodloff C, Koch D, Schaumann R. Epidemiology and antifungal resistance in invasive candidiasis. Eur J Med Res. 2011; 16: 187-95.
4. Miceli MH, Diaz JA, Lee SA. Emerging opportunistic yeast infections. Lancet Infect Dis. 2011; 11: 142-51.
5. Pappas PG, Rex JH, Sobel JD, Filler SG, Dismukes WE, Walsh TJ, et al. Guidelines for treatment of candidiasis. Clin Infect Dis. 2004; 38: 161-89.
6. Chandrasekar P. Management of invasive fungal infections: a role for polyenes. J Antimicrob Chemother. 2011; 66: 457-65.
7. Kothavade RJ, Kura MM, Valand AG, Panthaki MH. Candida tropicalis: its prevalence, pathogenicity and increasing resistance to fluconazole. J Med Microbiol. 2010; 59: 873-80.
8. Beyda ND, Lewis RE, Garey KW. Echinocandin resistance in Candida species: mechanisms of reduced susceptibility and therapeutic approaches. Ann Pharmacother. 2012; 46: 1086-96.
9. Bedin M, Gaben AM, Saucier C, Mester J. Geldanamycin, an inhibitor of the chaperone activity of hsp90, induces MAPK-independent cell cycle arrest. Int J Cancer. 2004; 109: 643-52.
10. Cowen LE, Lindquist S. Hsp90 potentiates the rapid evolution of new traits: drug resistance in diverse fungi. Science. 2005; 309: 2185-9.
11. DeBoer C, Meulman PA, Wnuk RJ, Peterson DH. Geldanamycin, a new antibiotic. J Antibiot (Tokyo). 1970; 23: 442-7.
12. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts-third edition: approved standard M27-A3. Wayne, PA: CLSI; 2008.
13. Lionakis MS, Lewis RE, Samonis G, Kontoyiannis DP. Pentamidine is active in vitro against Fusarium species. Antimicrob Agents Chemother. 2003; 47: 3252-9.
14. Odds FC. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother. 2003; 52: 1.
15. Picard D. Heat-shock protein 90, a chaperone for folding and regulation. Cell Mol Life Sci. 2002; 59: 1640-8.
16. Bishop SC, Burlison JA, Blagg BS. Hsp90: a novel target for the disruption of multiple signaling cascades. Curr Cancer Drug Targets. 2007; 7: 369-88.
17. Sreedhar AS, Mihaly K, Pato B, Schnaider T, Stetak A, Kis-Petik K, et al. Hsp90 inhibition accelerates cell lysis. Anti-Hsp90 ribozyme reveals a complex mechanism of Hsp90 inhibitors involving both superoxide- and Hsp90-dependent events. J Biol Chem. 2003; 278: 35231-40.
18. Bucci M, Roviezzo F, Cicala C, Sessa WC, Cirino G. Geldanamycin, an inhibitor of heat shock protein 90 (Hsp90) mediated signal transduction has anti-inflammatory effects and interacts with glucocorticoid receptor in vivo. Br J Pharmacol. 2000; 131: 13-6.
19. Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr, Calandra TF, Edwards JE Jr, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the infectious diseases society of America. Clin Infect Dis. 2009; 48: 503-35.
20. Coste A, Selmecki A, Forche A, Diogo D, Bougnoux ME, d'Enfert C, et al. Genotypic evolution of azole resistance mechanisms in sequential Candida albicans isolates. Eukaryot Cell. 2007; 6: 1889-904.
21. Sanglard D, Odds FC. Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect Dis. 2002; 2: 73-85.
22. Cowen LE. Hsp90 orchestrates stress response signaling governing fungal drug resistance. PLoS Pathog. 2009; 5: e1000471.
23. Cowen LE. The evolution of fungal drug resistance: modulating the trajectory from genotype to phenotype. Nat Rev Microbiol. 2008; 6: 187-98.
24. Li Y, Sun S, Guo Q, Ma L, Shi C, Su L, et al. In vitro interaction between azoles and cyclosporine A against clinical isolates of Candida albicans determined by the chequerboard method and time-kill curves. J Antimicrob Chemother. 2008; 61: 577-85.
25. Feng LJ, Wan Z, Wang XH, Li RY, Liu W. Relationship between antifungal resistance of fluconazole resistant Candida albicans and mutations in ERG11 gene. Chin Med J (Engl). 2010; 123: 544-8.
26. Maebashi K, Kudoh M, Nishiyama Y, Makimura K, Kamai Y, Uchida K, et al. Proliferation of intracellular structure corresponding to reduced affinity of fluconazole for cytochrome P-450 in two low-susceptibility strains of Candida albicans isolated from a Japanese AIDS patient. Microbiol Immunol. 2003; 47: 117-24.
27. Borah S, Shivarathri R, Kaur R. The Rho1 GTPase-activating protein Cgbem2 is required for survival of azole stress in Candida glabrata. J Biol Chem. 2011; 286: 34311-24.
28. LaFayette SL, Collins C, Zaas AK, Schell WA, Betancourt-Quiroz M, Gunatilaka AA, et al. Pkc signaling regulates drug resistance of the fungal pathogen Candida albicans via circuitry comprised of Mkc1, Calcineurin, and Hsp90. PLoS Pathog. 2010; 6: e1001069.